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Abstract
Background: Previous research has shown that ingestion of substances that enhance the body’s hydrogen ion
buffering capacity during high intensity exercise can improve exercise performance. The present study aimed to
determine whether the chronic ingestion of an alkalizing supplement, which purports to enhance both intracellular
and extracellular buffering capacity, could impact cardiorespiratory and performance markers in trained Nordic
skiers.
Methods: Twenty-four skiers (12 men, 12 women), matched for upper body power (UBP), were split into treatment
and placebo groups. The treatment group ingested Alka-Myte
®-based alkalizing tablets (1 tablet/22.7 kg body
mass/day) over seven successive days while the placebo group consumed placebo tablets (i.e., no Alka-Myte
®)a t
the same dosage. Prior to tablet ingestion (i.e., pre-testing), both groups completed a constant power UBP test,
three successive 10-sec UBP tests, and then a 60-sec UBP test. Next, skiers completed the 7-day ingestion of their
assigned tablets followed immediately by a repeat of the same UBP tests (i.e., post-testing). Neither the skiers nor
the researchers were aware of which tablets were being consumed by either group until after all testing was
complete. Dependent measures for analysis included heart rate (HR), oxygen consumption (VO2), minute ventilation
(VE), blood lactate (LA), as well as 10-sec (W10, W) and 60-sec (W60, W) UBP. All data were evaluated using a two-
factor multivariate repeated measures ANOVA with planned contrasts for post-hoc testing (alpha = 0.05).
Results: Post-testing cardiorespiratory (HR, VO2,V E) and LA measures for the treatment group tended to be
significantly lower when measured for both constant power and UBP60 tests, while measures of both 10-sec (W10:
229 to 243 W) and 60-sec UBP (W60: 190 to 198 W) were significantly higher (P < 0.05). In contrast, there were no
significant changes for the placebo group (P > 0.05).
Conclusions: Following the 7-day loading phase of Alka-Myte
®-based alkalizing tablets, trained Nordic skiers
experienced significantly lower cardiorespiratory stress, lower blood lactate responses, and higher UBP measures.
Thus, the use of this supplement appeared to impart an ergogenic benefit to the skiers that may be similar to the
effects expected from consuming well-studied extracellular buffering agents such as sodium bicarbonate.
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Background
Ergogenic aids are generally described as substances or
techniques used to improve athletic performance. Nutri-
tion supplements are often evaluated for their potential
as ergogenic aides by testing an athlete’s physiological
work capacity both before and after consumption of the
supplement. For example, numerous studies have tested
the efficacy of ingesting sodium bicarbonate or sodium
citrate to enhance intracellular and extracellular buffer-
ing capacity during high intensity exercise [1-3]. Theore-
tically, the ingestion of these substances can enhance the
body’s buffering capacity by absorbing the hydrogen ion
(H
+)b y - p r o d u c tf r o mi n t r a m u s c u l a rA T Ph y d r o l y s i s ,a s
well as ATP production via sarcoplasmic glycolysis [4].
During high intensity non-steady-state exercise, the rate
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+ ion production exceeds the muscle fiber’s ability
to buffer and/or remove the H
+ ions from the sarco-
plasm. As a result, both intracellular and extracellular
pH can decrease and subsequently contribute to muscu-
lar fatigue [5]. Thus, an enhanced buffering capacity has
the potential to ameliorate the impact of increased H
+
production on muscular work capacity during exercise.
Recently, an alkalizing nutrition supplement, hereafter
referred to as ANS (TAMER Laboratories, Inc., Shorline,
WA USA), has been marketed to endurance athletes as a
means for maximizing their intracellular and extracellular
buffering capacity via a daily mineral-based supplement.
According to the manufacturer, regular consumption of
this product will supplement the body’s ability to buffer
excess hydrogen ions resulting from metabolic acidosis
during high intensity exercise. As a result, the manufac-
turer claims that users can expect to experience increased
time to fatigue, lower blood lactate levels during steady-
state exercise, as well as a more rapid recovery of muscu-
lar strength following an intense muscular effort. The
supplement comes in tablet form, is consumed at a dose
relative to body mass (1 tablet per 22.7 kg), and contains
a proprietary blend of ingredients called Alka-Myte
®.A l l
of the ANS ingredients are allowed by both the U.S. and
World anti-doping agencies (i.e., WADA), while Alka-
Myte
® itself has been granted New Dietary Ingredient
(NDI) recognition by the Food and Drug Administration
(FDA).
Given the clearance by WADA and the FDA’sN D I
recognition, it surprising that there are no published con-
trolled studies to evaluate the efficacy of the performance-
related claims stated earlier. Therefore, the purpose of this
study was to investigate the potential influence of this
alkalizing nutrition supplement on previously validated
correlates of cross-country skiing performance (i.e., upper
body power) [6], as well as cardiorespiratory and blood
lactate responses in well-trained competitive Nordic skiers
both before and after a 7-day loading period.
Methods
Subjects and study design
Competitive Nordic skiers from the surrounding area
were recruited to visit the Movement Science/Human
P e r f o r m a n c eL a bo nt h eM o n t a n aS t a t eU n i v e r s i t yc a m -
pus on three separate occasions. Competitive skiers
familiar with the test protocols used for this study were
recruited to help minimize changes expected with ath-
letes performing lab-based performance tests for the first
time. All subjects were assigned into a treatment or pla-
cebo group, but neither the subjects nor the investigators
were aware of the either group’s identity until after all
data collection was complete (i.e., double-blind placebo-
controlled design).
Procedures
The first visit familiarized subjects with the testing proto-
col to be used for subsequent visits. Dependent measures
recorded during the second visit (i.e., pre-testing) served
to establish a baseline for both placebo and treatment
groups. Following a 7-day supplement loading phase, the
same tests were administered and dependent measures
collected during the third visit (i.e., post-testing) and then
compared directly to the pre-test measures. Dependent
measures of interest included measures of upper body
power (UBP), as well as cardiorespiratory and blood lac-
tate responses to the UBP tests.
During the first visit, subjects read and signed an
informed consent document approved by the Montana
S t a t eU n i v e r s i t yI n t e r n a lR e v i e wB o a r d( I R B ) .S u b j e c t s
then practiced with the testing protocols to be used during
their second (pre-testing) and third (post-testing) visits to
the lab. During the latter two visits, subjects completed a
submaximal double poling test (i.e., Constant-Power Test),
followed by three trials of a maximal intensity 10-sec
upper body power test (UBP10), and then finished with a
high intensity 60-sec UBP test (UBP60). An outline of the
test protocol administered for both pre- and post-testing
is outlined in Figure 1. The third lab visit (i.e., post-testing)
occurred within 24 hrs of completing the supplement
loading phase and repeated all test measures performed
during the second lab visit (Figure 1). The first visit lasted
approximately 30 minutes, while the other two visits lasted
60 minutes each.
Prior to their pre-testing arrival, subjects were randomly
assigned into one of two groups, placebo and treatment,
after being matched for their single highest W10 value
from the first visit UBP10 tests. For example, the two sub-
jects with the highest UBP10 values were randomly
assigned into the placebo and treatment groups, while
subsequently ranked pairs were similarly assigned. This
group assignment strategy was designed to place skiers
with similar caliber of UBP within each test group. The
treatment group would consume the ANS tablets while
the placebo group would consume placebo tablets during
the 7-day loading phase. The ANS tablet manufacturer
was able to provide both ANS and placebo tablets (see
description below) in sealed packages corresponding to
the two groups such that neither the subjects nor the
investigators knew the identity of either group.
Constant-power test
After a 5-minute warm-up on the double poling erg-
ometer at a self-selected power output, subjects were fit
with the metabolic measuring equipment and began dou-
b l ep o l i n ga tap o w e ro u t p u te q u i v a l e n tt o5 0 %o ft h e
value derived from the UBP10 test (W10, W; from first
visit). Using a constant poling cadence, the goal was to
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tion (VO2) within three minutes. The constant-power test
continued for 5-mins at which time the poling stopped to
draw a fingertip blood sample for the determination of
blood lactate. Two blood lactate samples were drawn at
approximately 30 and 120 seconds post-exercise (L1 and
L2, respectively; Figure 1). Prior to testing, the constant-
power test was intended to be a steady-state evaluation of
double-poling economy, but the ergometer load (50% of
W10) was too high for all subjects to maintain a steady-
state over five mins. Thus, the test is referred to as a con-
stant-power test rather than a test of double-poling
economy.
UBP Testing
Immediately following the constant-power test, subjects
rested for three minutes before performing three conse-
cutive trials of the UBP10 test. The 10-second test pro-
tocol is imbedded within a 30-second time period where
the skier spends the first 20 seconds ramping up power
output and poling cadence before exerting a maximal
double poling effort the final 10 seconds. The average
power output measured by the ergometer during the
final 10 seconds is recorded as the 10-second UBP
(W10, W). Each 30-sec test period was followed by 2.5
mins of rest prior to beginning the next 30-sec UBP10
test period. Subjects used the first trial as an additional
warm-up, using approximately 80% of maximal effort
during the last 10 seconds, before giving 100% effort for
the final two trials. Next, subjects rested again for an
additional 2.5 mins before performing a single 60-sec
test during which the goal was to achieve the highest
average power output over the entire 60 seconds (W60,
W) when starting from a dead stop. Thus, dependent
measures of UBP from these tests included both W10
(best of the last two of three trials) and W60 (one trial
only). During the UBP testing, the metabolic measure-
ment system was continuously measuring both HR and
VO2, while recovery measures of fingertip blood lactate
were measured at 30 and 120 secs immediate post-exer-
cise into each rest interval.
Previous research in our lab has determined that mea-
sures of both W10 and W60 correlate highly (r ≥ 0.92)
with 10 km classical Nordic ski race performance [6]. At
10 seconds of maximal effort, the UBP10 test was
designed to emphasize utilization of the ATP-PCr energy
system, whereas the UBP60 test was designed to empha-
size use of the glycolytic system. Thus, the basis for using
the W10 and W60 measures within the current study is
the supposition that any factor, such as a nutrition sup-
plement, that can influence measures of W10 and/or
W60 could potentially influence actual Nordic ski racing
performance as well.
Additional research in our lab has established reliabil-
ity characteristics for the W10 and W60 measures (i.e.,
day-to-day repeatability). A local group of competitive
Nordic skiers, each with 3+ years of ski racing experi-
ence, participated in two UBP testing visits in our lab
within 24 hours to two weeks of each other. During
each test visit, the UBP10 and UBP60 tests were admi-
nistered exactly as described for the present study. Spe-
cifically, three UBP10 tests were followed by a single
UBP60 test with a fixed amount of rest between tests.
Subjects who had never performed these tests prior to
the reliability study returned for a third visit (i.e., first
visit data were not used for data analysis). Mean values
for W10 and W60 across the first (Mean ± SE: 208 ± 21
W and 164 ± 16 W, respectively) and the second tests
(210 ± 22 W and 162 ± 16 W, respectively) did not dif-
fer significantly (P = 0.55 and 0.39, respectively). In
addition, intraclass correlations, whether computed
across two days of testing (ICC > 0.99) or extrapolated
for a single measurement (ICC > 0.98), were high, while
the standard errors of measurement for both W10 (±
2.7 W) and W60 (± 2.0 W) were low. Collectively, these
data indicate that the UBP10 and UBP60 test variables
were reliable when using trained Nordic skiers familiar
with the test protocols.
Nutrition supplement
The treatment group consumed ANS tablets at the pre-
scribed dosage of 1 tablet per 22.7 kg (i.e., 50 lbs) of
Figure 1 Diagram of timeline for testing protocol. The top row shows the order of upper body power (UBP) tests and rest intervals (RI), as
well as the total time accumulated (in parentheses) within each measurement period. The second row shows the approximate times at which
eight separate fingertip blood lactate samples were collected (indicated sequentially as L1-L8). Arrows within this same row point toward the
time period at which the test actually occurred (shown as darkened boxes within third row). Times within parentheses in the third row indicate
actual RI time following each test.
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consumed in the morning and the remainder at night
before going to bed. The ANS tablets are considered a
mineral supplement with each tablet containing calcium
(225 mg), magnesium (1 mg), potassium (36 mg), in a
proprietary blend of ingredients called Alka-Myte
®
(1000 mg). According to the manufacturer, there have
been no significant adverse events reported to acute or
chronic consumption of this supplement. The placebo
tablets were formulated by the ANS manufacturer to
have a similar size, color, shape, and texture as the ANS
tablets while lacking the Alka-Myte
® active ingredient.
Those subjects assigned to the placebo group consumed
a placebo tablet (maltodextrin-based) in the same dose
(1 tablet/22.7 kg body mass/day), frequency (split over
morning and evening), and duration (7 day ingestion
period) as prescribed for the treatment groups’ con-
sumption of ANS tablets.
Instrumentation
UBP Ergometer
A modified Concept 2 rowing ergometer (Concept 2
Model D; Morrisville, VT, USA), similar to that
described by Nilsson et al. [7], was used for all UBP
testing in this study. In place of the sliding seat on a
typical Concept 2 ergometer, a resistance-loaded trolley
is connected to the chain that turned the air-braked fly-
wheel. Two cross-country ski poles are attached to the
trolley such that pushing on the poles slides the trolley
backward along the rail. The chain, in turn, spins the
ergometer’s flywheel which thus provides resistance
each time the poles are pushed backward. As the poles
are brought back forward during the recovery phase, the
trolley is pulled forward by the pole tips along the rail
with very little resistance. Additional ergometer modifi-
cations included a longer steel rail than a typical rowing
ergometer (2.8 m instead of 1.4 m), as well as a platform
mounted above and to the front of the rail on which the
skier stands during testing. Identical to the Concept 2
ergometer, the modified ergometer provides a continu-
ous digital display of power output in watts (using the
Concept 2 PM3 digital monitor), as well as a recording
of average power output over user-defined work periods.
Previous research has reported the test-retest of power
measurements using the Concept 2 ergometer to have
been reliable in tests lasting 90 to 420 seconds [8]. The
ski poles used for ergometer testing (Toko P232 poles;
Mammut Sports Group AG, Seon, Switzerland; Swix
synthetic cork grips and Swix Pro Fit straps; Swix Sport
USA Inc., Boston, MA), available in 5-centimeter incre-
ments between 135 cm and 170 cm, were fit to within
2 . 5c mo fe a c hs u b j e c t ’s own classic racing pole length.
The length of poles used by each subject during the first
visit was recorded and used for testing during each sub-
sequent visit.
Indirect calorimetry
Based upon unreported pilot testing prior to this study,
we speculated that one or more cardiorespiratory para-
meters could be influenced by ANS if there was a subse-
quent influence on measures of UBP. Thus, measures of
oxygen consumption (VO2, L/min), minute ventilation
(VE, L/min), and heart rate (BPM) were incorporated into
the protocol. Using standard indirect calorimetry proce-
dures, a portable metabolic system (Oxycon Mobile,
Viasys Healthcare, Yorba Linda, CA) was worn by each
subject using a modified hydration backpack (Slipstream;
Camelbak Products, LLC; Petaluma, CA). The oxygen
and carbon dioxide analyzers were calibrated prior to
each test using a certified gas mixture. Both analyzers, as
well as the ventilation meter, were calibrated prior to
each test according to the manufacturer’s guidelines. The
metabolic system collected breath-by-breath data which
w a st h e nr e p o r t e da s6 0 - s e c( f o rt h eC o n s t a n t - P o w e r
Test) and 5-sec sample intervals (UBP10 and UBP60
tests) for both VO2 and VE. Using a Polar Accurex Plus
heart rate monitor strap (Polar Electro, Inc., Lake Suc-
cess, NY), the metabolic system also collected and
reported heart rate (BPM) data over the same 60- and 5-
sec intervals. During testing, the raw data signals from
the metabolic system, including that for HR, were trans-
mitted via telemetry to a computer base station within
20 meters of the UBP ergometer (telemetry range is <
1000 meters).
Blood lactate analyzer
Using the handheld Lactate Pro analyzer (Arkray, Inc.,
Kyoto, Japan), whole blood lactate from a single finger-
tip blood droplet is analyzed in 60 seconds. The reagent
test strip for the meter requires 5 μl of whole blood,
sampled by capillary action, to initiate an internal che-
mical reaction and subsequent electrical current propor-
tional to the lactate concentration. Previous research has
shown that while correlations between blood lactate
values from different analyzers using the same blood
sample can be high (r ≥ 0.97), the absolute difference
between monitors can be practically meaningful (± 2-3
mM) over the physiological range of 1-18 mM). To help
control for known confounders to the measurement of
blood lactate for this study, several precautions were
taken. First, the monitor’s Check Strip (allows a self-
check by the monitor) and Calibration Strip (comes
with each box of reagent strips) was utilized prior to
each test session. Second, it is known that lactate con-
centrations can vary between boxes of test strips for the
same blood sample. To help control for this variability,
a single box of test strips was assigned to each subject
for both pre- and post-testing lactate measures. Third,
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able due to inconsistent skin cleaning and sampling pro-
cedures. Lastly, it is possible for individual Lactate Pro
meters to provide slightly variable lactate measures for
the same blood sample. These last two factors were
mitigated with standard measurement protocols, using
the same researcher for all lactate testing and by using
the same meter for each subject for both pre- and post-
testing. Given the controls mentioned above, Pyne et al.
[9] concluded that “the Lactate Pro is accurate, reliable
and exhibits a high degree of agreement with other lac-
tate analyzers”.
Diet and exercise log
Both diet and recent exercise habits could confound the
measures of UBP, as well as the cardiorespiratory and
blood lactate responses by influencing intracellular and/
or extracellular buffering capacity. To address this issue,
we attempted to control these factors within each subject
rather than across all subjects. Using a simple 2-page diet
and exercise log, subjects recorded the general types and
amounts of food consumed during the 48 hrs preceding
testing. Subjects also used the log to record the types of
exercise (mode, intensity, duration) in which they partici-
pated during the same time period. Subjects were asked
to refrain from high intensity and long duration activities
for the 24 hrs preceding both pre- and post-testing. After
an evaluation of the log by researchers at the end of the
pre-testing visit, subjects kept the logs for reference dur-
ing the 48 hrs prior to the post-testing visit. Ideally, sub-
jects were to use the 2-page log as a reference so that
their diet and activity habits were relatively similar prior
to pre- and post-testing lab visits. An additional 2-page
log was maintained for both diet and exercise for the
48 hrs prior to post-testing. At the end of the post-testing
visit, the log was again reviewed by researchers to verify
what was recorded. Analyses were not performed on the
nutrition and exercise log data, but rather used as a
method to assist subjects with adhering to the require-
ments of the study.
Lastly, subjects were asked to use the 2-day logs as a
means for recording any perceived side effects of ingesting
the placebo or ANS tablets. Subjects were instructed to
consider unusual or unexpected gastrointestinal (GI) dis-
tress (e.g., stomach aching or cramping, excess gas), or any
other unusual physiological sensations, as possible side
effects.
Statistical analyses
Summary measures of power output (W10, W60), cardior-
espiratory measures from the constant-power test (60-sec
HR, VO2,V E), peak cardiorespiratory measures from the
UBP10 and UBP60 tests (5-sec HR, VO2,V E), as well as
recovery blood lactate measures following each test (L1-
L8) were evaluated using multivariate two-factor (group ×
time) repeated measures analysis of variance (ANOVA).
Post-hoc testing was performed using planned contrasts to
compare pre-testing and post-testing values within
placebo and treatment groups (alpha = 0.05). Using the
procedures described by Cohen [10] and the UBP reliabil-
ity reported by previously [6], a sample size of 10-12 sub-
jects per group were needed to detect a mean difference of
10-15 W (Power = 0.80 and alpha = 0.05).
Results
A total of 26 subjects were recruited but only 24 were able
to complete all three lab visits. The demographics for the
remaining 24 subjects (12 per group), summarized in
Table 1 show an equal representation of men and women.
This latter characteristico ft h et w og r o u p sw a sn o t
planned apriori, but rather the result of the W10 matching
and splitting strategy. All subjects had been Nordic ski
racing between five and 20 years with all but one subject
training and competing in Nordic ski races during the
recently completed ski season. The 2-day diet and exercise
logs for both pre- and post-testing were collected from all
subjects. According the subjects, the act of recording diet
and exercise habits prior to pre-testing was useful for
monitoring and controlling these behaviors prior to the
post-testing visit. Lastly, reports of perceived side effects
were relatively minimal. Four subjects within the placebo
group reported usual GI disturbances (upset stomach over
7 days; unusual gas over 2 days) or events (bad taste to
Table 1 Descriptive statistics for demographic variables corresponding to placebo and treatment groups
Group Gender Sample
Size
Age
(years)
Body Height
(cm)
Body Mass
(kg)
Placebo Men 7 29 ± 9
(20-47)
178.5 ± 7.8
(167.1-188.5)
76.9 ± 8.8
(66.1-90.5)
(n = 12) Women 5 29 ± 11
(18-44)
167.6 ± 4.6
(162.4-171.5)
61.3 ± 8.5
(52.4-75.0)
Treatment Men 7 27 ± 12
(19-52)
180.6 ± 9.1
(169.2-195.0)
72.7 ± 3.4
(68.5-78.2)
(n = 12) Women 5 21 ± 3
(18-26)
167.8 ± 4.7
(163.3-175.1)
63.7 ± 5.3
(57.6-70.7)
NOTE: All values expressed as Mean ± SD (Range)
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only one subject in the treatment group noted unusual
bowel movement activity while ingesting the ANS tablets.
None of these perceived side effects, however, were
reported to have limited or changed anything about the
affected subjects’ usual diet or exercise habits.
Measures of UBP
Mean values for W10 and W60 across test groups and
UBP tests (Tables 2 and 3, respectively) show that W60
values were approximately 75-85% of the W10 values, an
observation consistent with previous W10 and W60 test-
ing in collegiate Nordic skiers [6]. Mean W10 values for
the placebo group were statistically similar across familiar-
ization, pre-testing, and post-testing trials (241-250 W;
Table 2). Similarly, W60 for the placebo group did not dif-
fer significantly across the three lab visits (186-188 W;
Table 3). In contrast, post-testing values for both W10
(Table 2) and W60 (Table 3) were significantly higher for
the treatment group relative to familiarization and pre-
testing values. Post-testing W10 values were +14 W higher
than pre-testing values for the treatment group compared
with only +4 W higher for the placebo group. Similarly,
post-testing W60 values were +8 W higher than pre-test-
ing values for the treatment group compared with only +2
W for the placebo group. Figures 2 and 3 illustrate the
range of individual changes in W10 and W60, respectively,
from pre- to post-testing for both placebo and treatment
groups.
Cardiorespiratory measures
Summary statistics for measures of HR, VO2,a n dV E are
presented in Tables 4, 5, 6, respectively. Pre- to post-test-
ing mean HR, VO2, and VE values for the placebo group
were statistically similar across the UBP tests. The one
exception was mean post-testing VO2 for the UBP60 test
which was significantly higher than the placebo group’s
pre-testing value. Similarly, cardiorespiratory measures for
the treatment group did not different significantly between
pre- and post-testing conditions for all three trials of the
UBP10 test. However, post-testing HR and VO2 were both
significantly lower than pre-testing values for the treat-
ment group’s constant-power test. Additionally, all post-
testing cardiorespiratory variables (HR, VO2,a n dV E)f o r
the UBP60 test were significantly lower than the group’s
pre-testing values.
Blood lactate measures
Summary statistics for blood lactate measured at eight
separate time points (L1-L8) are shown in Table 7. Pre-
and post-testing lactate values were statistically similar
for the first seven time points for the placebo group.
The placebo group’s post-testing value for the eighth
time (L8) point was significantly higher than the pre-
testing value (10.3 ± 0.6 vs 9.7 ± 0.6 mmol/L). Pre- and
post-testing values for the treatment group were also
statistically similar for L2-L6, but post-testing values for
L1, L7, and L8 were all statistically lower than their cor-
responding pre-testing values.
Discussion
The present study was designed to evaluate the potential
influence of an Alka-Myte
®-based alkalizing nutrition
supplement (ANS) on cardiorespiratory, blood lactate,
and upper body power (UBP) measures in trained Nordic
skiers. Collectively, the results from the constant-power
and UBP60 tests suggest that, in comparison to ingesting
the placebo, a 7-day supplement loading period imparted
what could be interpreted as an ergogenic effect on sev-
eral dependent variables for two of the three tests admi-
nistered. For example, post-testing cardiorespiratory (HR,
VO2,V E) and blood lactate values tended to be lower for
both constant-power and UBP60 tests while the ability to
Table 2 Summary of 10-sec upper body power (W10) results for familiarization, pre-testing, and post-testing visits
Group Best W10 for the Familiarization
Trial (W)
Best W10 for the
Pre-Testing
Trials (W)
Best W10 for the
Post-Testing
Trials (W)
Placebo
(n = 12)
241 ± 30 246 ± 31 250 ± 31
Treatment
(n = 12)
225 ± 28 229 ± 29 †243 ± 29
NOTE: All values expressed as Mean ± SE.
†Mean post-testing W10 for the treatment group was significantly higher than the treatment groups’ mean values for familiarization and pre-testing.
Table 3 Summary of 60-sec upper body power (W60)
results for familiarization, pre-testing, and post-testing
visits
Group W60 for the
Familiarization
Trial (W)
W60 for
Pre-Testing
Trial (W)
W60 for
Post-Testing
Trial (W)
Placebo
(n = 12)
187 ± 24 186 ± 23 188 ± 22
Treatment
(n = 12)
188 ± 22 190 ± 24 †198 ± 25
NOTE: All values expressed as Mean ± SE
†Mean post-testing W60 for the treatment group was significantly higher than
the treatment groups’ mean values for familiarization and pre-testing
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significantly higher following ANS supplementation. In
contrast, results from the UBP10 tests provided a less
definitive ergogenic effect for the treatment group despite
the fact that the treatment group experienced a signifi-
cant increase in W10 over the placebo group’s lack of sig-
nificant change.
Constant-power test
The constant-power test involved double-poling on the
ergometer for five minutes at an UBP equivalent to 50% of
W10. This test was originally intended to elicit steady-
state cardiorespiratory and blood lactate responses and
thus provide measures of moderate-high intensity double-
poling economy. In fact, more than half of the subjects
showed small but steady increases in cardiorespiratory
parameters during the last 2-3 minutes of the test (i.e.,
non-steady-state responses). The subjects most likely to
experience non-steady-state responses to the protocol,
which were evenly split across placebo and treatment
groups, were those with the highest W10 values. Regard-
less, the treatment group’s change from pre-testing to
post-testing for HR (164 to 159 BPM), VO2 (2.84 to 2.77
L/min), blood lactate (7.0 to 5.5 mmol/L) were all signifi-
cantly lower for the constant-power test whereas signifi-
cant changes for the placebo group were not observed.
This suggests that the treatment group experienced less
cardiorespiratory and/or muscular stress while double-pol-
ing at the same mean power output following seven days
of ANS supplementation.
Interestingly, the above observations are similar to pre-
vious evaluations of the influence of pre-exercise meta-
bolic alkalinization on VO2 kinetics [11-13]. For example,
K o l k h o r s te ta l .[ 1 2 ] ,u s i n gpre-exercise sodium bicarbo-
nate (NaHCO3) ingestion to induce metabolic alkalosis
prior to high intensity exercise, found that the rapid com-
ponent of VO2 kinetics was slowed when compared to the
control condition. Berger et al. [11] also found pre-exercise
NaHCO3 ingestion to influence VO2 kinetics during high
intensity exercise, but they also found that end-exercise
Figure 2 Individual changes in 10-sec upper body power (Delta W10, W). These data represent measured changes following a 7-day
nutrition supplement loading period (pre- versus post-testing) for both placebo (A) and treatment (B) groups. Note that values for men are
indicated with dashed lines and open squares (□), women by dashed lines and open circles (○), and change in the group mean is indicated
with a solid line and closed diamond (♦). The horizontal dotted line indicates no change between pre- and post-testing.
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Page 7 of 12VO2 was significantly lower (2.79 versus 2.88 L/min) at the
end of six minutes of high intensity exercise when com-
pared to the control condition. The present study
observed a similar decrease in VO2 (2.84 to 2.77 L/min;
Table 5) with a concomitant decreases in HR (164 to 159
BPM; Table 4) and blood lactate (7.0 to 5.5 mmol/L for L1;
Table 7). Thus, while blood pH changes were not directly
monitored during the present study, the cardiorespiratory
Figure 3 Individual changes in 60-sec upper body power (Delta W60, W). These data represent measured changes following a 7-day
nutrition supplement loading period (pre- versus post-testing) for both placebo (A) and treatment (B) groups. Note that values for men are
indicated with dashed lines and open squares (□), women by dashed lines and open circles (○), and change in the group mean is indicated
with a solid line and closed diamond (♦). The horizontal dotted line indicates no change between pre- and post-testing.
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Page 8 of 12changes observed with ANS supplementation were consis-
tent with prior investigations of NaHCO3 supplementation
on VO2 kinetics. This observation appears to support the
claim by the ANS manufacturer that regular use of this
supplement can enhance metabolic buffering capacity and
lower blood lactate responses during high intensity, sub-
maximal exercise. Of course, further testing should be per-
formed to directly evaluate this claim.
UBP10 Test
The UBP10 test was administered as three successive trials
with the first serving as a practice and the last two per-
formed maximally. Following the 7-day loading phase, both
groups increased mean W10 values, but only the treatment
group’s post-testing values increased significantly relative
to pre-testing values (229 to 243 W; Table 2). However,
neither cardiorespiratory nor blood lactate measures chan-
ged significantly for either group. Additionally, pre- to
post-change in W10 values (Figure 2) showed that most
subjects within both groups actually increased W10 from
pre- to post-testing (9 of 12 for placebo group and 11 or
12 for treatment group).
There are several factors that may have contributed to
the UBP10 tests lack of complete consistency with those
from the constant-power and UBP60 tests. First, given
that each of these tests required only 10-secs of maximal
effort followed by 2.5 mins of complete rest between each
trial, significant pre- to post-changes related to the UBP10
tests were not necessarily expected. However, for the sake
of consistency, we chose to administer the UBP10 and
UBP60 tests in the same manner as that described for the
original development and validation of these tests [6]. In
addition, pilot testing (prior to this study) with a protocol
that required eight successive UBP10 tests with 30-sec rest
intervals suggested that both peak HR and W10 were
responsive to a 7-day ANS loading phase. Thus, the choice
to be consistent with previous testing protocols, in addi-
tion to the brevity of the actual test time (10 seconds) and
length of total rest (2.5 mins), probably contributed to the
lack of meaningful cardiorespiratory or blood lactate
changes in the treatment group. A second contributing
factor is highlighted by the graphs of pre- to post-change
in W10 (Figure 2). Close evaluation of these graphs indi-
cate that most subjects increased the W10 regardless of
group assignment. Thus, despite the previous evaluation
of UBP10 reliability described in the Methods section, it
seems likely that the UBP10 test was more skill dependent
than the UBP60 test. This also suggests that the single
familiarization visit was not sufficient for all subjects to
achieve repeatable W10 values with successive visits.
UBP60 Test
The UBP60 test, the last of the three UBP tests adminis-
tered, required skiers to maintain the highest average
UBP over the course of 60 seconds of double-poling.
Interestingly, not only did peak values for HR (177 versus
Table 4 Summary heart rate (BPM) measures resulting from five upper body power tests
Group Test
Period
Constant
Power
Test
UBP10
Test
Trial #1
UBP10
Test
Trial #2
UBP10
Test
Trial #3
UBP60
Test
Placebo
(n = 12)
Pre-Test 161 ± 4 156 ± 2 167 ± 2 169 ± 2 182 ± 2
Post-Test 160 ± 4 157 ± 3 167 ± 3 169 ± 3 183 ± 2
Treatment
(n = 12)
Pre-Test 164 ± 6 158 ± 5 165 ± 4 166 ± 4 184 ± 4
Post-Test †159 ± 6 160 ± 6 169 ± 6 167 ± 4 †177 ± 3
NOTE: All values expressed as Mean ± SE; UBP10 = 10-sec upper body power test; UBP60 = 60-sec upper body power test
†Post-test measure of heart rate for Constant-Power and UBP60 tests were significantly lower than pre-test measure within the treatment group (P < 0.05)
Table 5 Summary oxygen consumption (VO2, L/min) measures resulting from five upper body power tests
Group Test
Period
Constant
Power
Test
UBP10
Test
Trial #1
UBP10
Test
Trial #2
UBP10
Test
Trial #3
UBP60
Test
Placebo
(n = 12)
Pre-Test 2.68 ± 0.28 2.29 ± 0.22 2.55 ± 0.20 2.63 ± 0.19 3.14 ± 0.24
Post-Test 2.72 ± 0.30 2.47 ± 0.23 2.88 ± 0.23 2.74 ± 0.21 ‡3.38 ± 0.26
Treatment
(n = 12)
Pre-Test 2.84 ± 0.29 2.34 ± 0.18 2.61 ± 0.17 2.65 ± 0.19 3.43 ± 0.25
Post-Test †2.77 ± 0.28 2.33 ± 0.21 2.67 ± 0.23 2.68 ± 0.20 ‡3.26 ± 0.26
NOTE: All values expressed as Mean ± SE; UBP10 = 10-sec upper body power test; UBP60 = 60-sec upper body power test
†Post-test measure of VO2 for Constant -Power test was nearly significantly lower than pre-test measure within the treatment group (P < 0.10)
‡Post-test measure of VO2 for UBP60 test were significantly different than pre-test measure within the corresponding test group (P < 0.05)
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Page 9 of 12184 BPM; Table 4), VO2 (3.26 versus 3.43 L/min; Table 5),
and minute ventilation (VE - 153.3 versus 163.5 L/min;
Table 6) all decreased significantly for post-testing in the
treatment group, but the same group also generated more
UBP following the 7-day loading phase (190 to 198 W for
W60; Table 3). In addition, the last two post-testing recov-
ery blood lactate measures (L7 and L8) for the UBP60
tests were significantly lower for the treatment group. In
contrast, the placebo group showed no change in W60,
peak HR, or peak VE while also showing significant
increases in peak VO2 (Table 5) and the final recovery
blood lactate (L8; Table 7) following the placebo group’s
7-day loading period. Collectively, these observations sug-
gest that the treatment group experienced less cardiore-
spiratory stress and lower recovery blood lactate values
while generating more average power during post-testing.
In contrast to the individual changes in W10 between
pre- and post-testing (Figure 2), the individual changes in
W60 (Figure 3) showed that all treatment group subjects
increased W60 from pre- to post-testing while the placebo
groups’ responses were highly variable. Again, in combina-
tion with the significant changes in cardiorespiratory and
recovery blood lactate measures, the treatment groups’
post-testing responses to the ANS loading suggests possi-
ble ergogenic benefits.
G i v e nt h a tt h eU B P 6 0t e s tw a st h el a s to ft h r e et e s t s
administered, as well as the 60-sec test time for testing,
the UBP60 test was though apriori to be most sensitive
to creating significant cardiorespiratory and blood lactate
changes following the ANS loading. Numerous studies
investigating the influence of NaHCO3 supplementation
on indicators of performance have used 30-120 sec time
intervals for testing, as well as repeat test intervals follow-
ing fixed rest intervals, to emphasize the use of non-
mitochondrial ATP production and subsequent intracel-
lular acidosis (for a review see Williams [14]). Thus,
whether acidosis was induced acutely by the 60-sec time
frame of the UBP60 test, or by the accumulation of three
tests administered successively, or by a combination of
these factors, the influence of ANS loading on the treat-
ment group was similar to what has been described for
NaHCO3 supplementation. Specifically, the treatment
group was capable of generating higher W60 values while
experiencing lower cardiorespiratory stress and lower
recovery blood lactate values. These observations may
support the claims by the ANS manufacturer of a more
rapid recovery of muscle function following prior intense
muscular efforts.
Possible mechanism for observed effects?
The Alka-Myte
®-based supplement evaluated by this
study is purported to be a mineral-based intracellular
and extracellular alkalizing agent that helps minimize the
influence of metabolic acidosis and muscle fatigue during
Table 6 Summary minute ventilation (VE, L/min) measures resulting from five upper body power tests
Group Test
Period
Constant
Power Test
UBP10
Test
Trial #1
UBP10
Test
Trial #2
UBP10
Test
Trial #3
UBP60
Test
Placebo
(n = 12)
Pre-Test 100.6 ± 11.5 87.9 ± 10.0 99.4 ± 10.2 110.4 ± 9.4 147.2 ± 12.1
Post-Test 100.7 ± 13.2 92.3 ± 9.9 109.8 ± 9.9 113.9 ± 10.1 148.6 ± 13.2
Treatment
(n = 12)
Pre-Test 104.6 ± 11.7 102.9 ± 7.7 126.0 ± 12.8 129.7 ± 10.3 163.5 ± 12.0
Post-Test 101.7 ± 10.6 97.3 ± 9.8 122.4 ± 11.8 132.1 ± 12.9 †153.3 ± 11.1
NOTE: All values expressed as Mean ± SE; UBP10 = 10-sec upper body power test; UBP60 = 60-sec upper body power test
†Post-test measure of VE for UPB60 test was nearly significantly lower than pre-test measures within the treatment group (P < 0.10)
Table 7 Summary measures for eight (L1-L8) fingertip blood lactate analyses (mmol/L) from tests of upper body
power
Constant-Power Test UBP10 Tests UBP60 Test
Group †L1 L2 Trial #1
L3
Trial #2
L4
Trial #3
L5
L6 L7 L8
Placebo
Pre-Testing
Post-Testing
5.3 ± 0.6
4.9 ± 0.6
5.0 ± 0.6
5.0 ± 0.7
5.1 ± 0.6
4.9 ± 0.6
5.6 ± 0.5
5.6 ± 0.5
6.4 ± 0.6
6.6 ± 0.5
9.2 ± 0.5
9.4 ± 0.5
9.8 ± 0.6
10.3 ± 0.6
9.7 ± 0.6
‡10.3 ± 0.6
Treatment
Pre-Testing
Post-Testing
7.0 ± 0.6
‡5.5 ± 0.6
5.8 ± 0.8
5.7 ± 0.7
6.1 ± 0.7
5.6 ± 0.7
6.6 ± 0.6
6.3 ± 0.6
7.2 ± 0.6
7.2 ± 0.7
9.8 ± 0.8
9.4 ± 0.7
10.9 ± 0.7
‡9.8 ± 0.7
10.4 ± 0.7
‡9.4 ± 0.6
NOTE: All values expressed as Mean ± SE; UBP10 = 10-sec upper body power test; UBP60 = 60-sec upper body power test. Sample sizes remained at 12 subjects
per group for both pre- and post-testing
†The eight blood lactate samples (L1-L8) are labeled the same as those shown within Figure 1
‡Mean post-testing blood lactate value differed significantly (P < 0.05) from corresponding pre-testing value within the same test group
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Page 10 of 12high intensity exercise. Classically, this type of buffering
agent refers to mitigating the impact of excess intramus-
cular lactic acid on decreased intracellular pH and the
subsequent performance decrement of cross-bridge
cycling and muscle force generation [4,5]. However, the
lactic acid hypothesis as a driving force behind metabolic
acidosis and muscle fatigue is not supported by the cur-
rent body of research [4,5]. The creation of metabolic
acidosis during high intensity exercise has been shown to
occur when the rate of ATP hydrolysis (i.e., an indicator
of ATP demand) exceeds the rate of ATP production by
the mitochondria [4]. As such, the formation of cytosolic
lactic acid from pyrurate is actually caused by an
increased cytosolic H
+ concentrations rather than lactic
acid being the cause of increased H
+ concentrations.
Thus, despite the frequent confusion in research and lay-
literature regarding the primary cause of metabolic acido-
sis, measures of blood lactate during and immediately fol-
lowing exercise are still considered reasonable correlates
of intracellular changes in pH for whole-body exercise
[4].
Despite the lack of support for the lactic acid hypothesis,
there is general agreement that metabolic acidosis can
adversely influence muscle function [5]. Thus, any nutri-
tion supplement that can potentially dampen the onset or
severity of metabolic acidosis during high intensity exer-
cise can also potentially influence muscle function and
thus whole-body performance. For example, dosing with
NaHCO3 [15,16], sodium citrate [1,16], or sodium lactate
[16] have all been shown to positively influence physical
performance. One likely mechanism by which these sup-
plements influence metabolic acidosis is by improved
intracellular and/or extracellular buffering of H
+. However,
since extracellular (i.e. plasma) acidosis will not occur until
minutes after a bout of high intensity exercise, it is possi-
ble that improved extracellular buffering acts to increase
the intra- to extracellular H
+ gradient during exercise [17].
In the present study, neither arterial blood samples nor
muscle biopsy samples were collected for the measure-
ment of pH or buffering capacity so we cannot be certain
to what degree that the Alka-Myte
®-based supplement
was acting as an intra- or extracellular alkalizing agent.
Future experimentation with this supplement should
incorporate these measures to address this limitation.
One hypothesized mechanism relating the influence of
intracellular metabolic acidosis on muscle fatigue is a pos-
tulated influence on the central nervous systems’ ability to
recruit the affected muscle fibers [5]. For example, Street
et al. [17] has shown that extracellular alkalosis induced by
sodium citrate ingestion will influence the accumulation of
interstitial H
+, which, in turn, was coupled to an increase
in potassium ions (K
+). Since the accumulation of intersti-
tial K
+ has been shown to reduce muscle excitability [18],
the lowering interstitial K
+ has also been postulated to
improve performance of the affected muscle [19]. It has
also been suggested that local pH and concentrations of
K
+ are related to local vasodilatory mechanisms [20]. In
short, induced extracellular alkalosis may influence blood
flow indirectly through an influence on interstitial K
+
concentrations.
Study limitations
As a pilot evaluation of this Alka-Myte
®-based supple-
ment, this study was designed simply to describe the
effects of a proscribed supplementation routine rather
than decipher possible mechanisms. Thus, future studies
should verify the potential ergogenic effects of this supple-
ment with more invasive measures of changes in blood
pH. In addition, it is not known whether a 7-day loading
phase was necessary for the observed treatment effects or
whether a longer loading phase, or even a higher daily
dosage, would elite different results. Thus, issues related to
a dose-response paradigm must be addressed with future
studies.
Conclusions
In response to seven days of ingesting an Alka-Myte
®-
based alkalizing nutrition supplement, trained Nordic
skiers experienced significant changes in cardiorespiratory,
blood lactate, and upper body power output measures. All
of the observed changes were consistent with those of an
ergogenic aid for trained Nordic skiers. In contrast, a simi-
lar group of Nordic skiers consuming a placebo did not
experience similar changes. Thus, the use of this supple-
ment appeared to impart an ergogenic benefit to the skiers
that may be similar to the effects expected from consum-
ing well-studied extracellular buffering agents such as
sodium bicarbonate.
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